Tesamorelin – The Visceral Fat Peptide

Tesamorelin is the growth-hormone peptide with one very specific target: visceral fat — the deep abdominal fat packed around the organs, not the layer that pinches. It's the same compound behind Egrifta, the only FDA-approved medication indicated for reducing that particular kind of fat. 🎯 Tesamorelin — The Visceral Fat Peptide Aimed at the deep belly fat, not at the scale. What it is, in plain English There are two kinds of belly fat. The subcutaneous layer sits just under the skin — that's the part that pinches. Visceral fat sits deeper, wrapped around the liver, pancreas, and intestines. The deep kind is the one tied to metabolic health, and it's notoriously stubborn: it can stay put even while the scale is moving. Tesamorelin is a GHRH analog. Rather than supplying growth hormone from the outside, it signals the pituitary to release the body's own growth hormone in its natural rhythm. It's the active compound in Egrifta, which the FDA approved for reducing excess visceral abdominal fat in a specific patient population. How it's different 🎯 Studied specifically for deep visceral abdominal fat, not total body weight 🌙 Prompts the body's own growth-hormone pulses instead of replacing them 🧬 The only compound in this class carrying an FDA approval tied to visceral fat 🔗 Works on the same growth-hormone pathway associated with sleep quality and recovery Why people reach for it Calorie deficits and cardio move total weight — but the deep abdominal fat doesn't always follow, which is the frustration behind a flat scale reading that still doesn't match the mirror. Tesamorelin is the compound people look at when the target is that deep midsection fat specifically. Its close relatives in this catalog point in different directions: Sermorelin and CJC-1295 / Ipamorelin are the ones people reach for when the goal is sleep, recovery, and general anti-aging on the growth-hormone axis. Tesamorelin is often discussed alongside a supervised weight-loss program rather than in place of one. Direct growth hormone Tesamorelin Approach Supplies GH from outside Signals the pituitary to release its own Release pattern Flat, externally set The body's own natural pulses Studied target Broad Deep visceral abdominal fat Is it a fit? That's a conversation, not a checkout button. Growth-hormone pathway compounds affect blood sugar, so a provider's review matters — particularly for anyone with diabetes or prediabetes, anyone who is pregnant or breastfeeding, and anyone with a history of cancer. Take the 60-second peptide quiz or message our team, and our providers can point the way. 🔬 For the science-minded Tesamorelin is a synthetic analog of growth-hormone-releasing hormone. It binds GHRH receptors in the anterior pituitary, stimulating endogenous growth-hormone secretion, which in turn raises IGF-1 — a secretagogue approach rather than exogenous GH replacement, so the pulsatile release pattern and the body's own feedback loops stay intact. The registration trials studied HIV-associated lipodystrophy and reported reductions in visceral adipose tissue on the order of 15% over 26 weeks in that population; separate research has looked at liver fat in NAFLD and at cognition in mild cognitive impairment. Because raising growth hormone can reduce insulin sensitivity, glucose is the parameter clinicians watch most closely, and IGF-1 is typically monitored as well. Educational only — not medical advice. Peptides discussed here are research compounds; whether any is appropriate is a decision between a patient and their licensed provider.